Scholars Central

Conference abstract

Gaps in analytical methods registered by pharmaceutical labs

Authors: Joaquin Perea Leria, Javier Garea Barriga

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

First of all, it???s important to talk about the current regulation where we are. We are in the Europe Union, where the Regulatory Authorities of each country is responsible of the approval of the marketing authorization of drugs and medical devices except the cases of centralized procedure (innovative products). These approvals are accepted by the member countries of the European Union once they are approved by European Medicines Agency (EMA). The main issues founded come from analytical methods approved by mutual recognition procedures. During the author???s professional experience he has observed many different gaps in the approved analytical methods. In his opinion there could be several factors involving the following: evaluators poorly trained in the evaluation of analytical methods, the ability of the pharmaceutical industry to get the approval of methods that don???t comply with the pharmacopoeia requirements, lack of data integrity in data management. The purpose of this conference is to talk about the gaps founded, how they can modify the analytical results and the responsibilities of each department involved in the validation of the analytical methods. The author is going to talk about concrete cases without mentioning specific laboratories but showing the weaknesses of their way of work. Some of the gaps he refers to are: dissolution methods with stirring speed of 200 rpm; use of non-standardized sinkers (ph Eur proposition); hiding chromatographic parameters; non-traceable chromatograms and no system suitability established. To conclude, we don???t have to panic as most of the gaps founded are due to a lack of updates of the dossiers. This updates require an administrative process, such as variations, which means paying additional fees. Due to this, the pharmaceutical industry tries to widen the time to make these payments. This situation could be solved if the Regulatory Authorities control the dossiers updates in a more exhaustive way.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Joaquin Perea Leria”
  • BylineArticles whose byline prints “Javier Garea Barriga”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels